Development and Optimization of an Ex Vivo Colloidal Stability Model for Nanoformulations
- 132 Downloads
Nanotechnology is having a significant impact in the drug delivery systems and diagnostic devices. As most of the nanosystems are intended to be administered in vivo, there is a need for stability models, which could simulate the biological environment. Instability issues could lead to particle aggregation and in turn could affect the release of the drug from the nanosystems and even lead to clogging of the systemic blood circulation leading to life-threatening situation. We have developed an ex vivo colloidal stability model for testing the stability of nanosystems over a period of 48 h, which is the typical residence time of the nanoparticles in vivo. Tissue homogenates of rat spleen, brain, kidney, and liver were stabilized and optimized for the study; additionally, plasma and serum were used for the same. Poly (lactide-co-glycolic acid) nanoparticles were used as model nanosystem, and no significant change was found in the size and polydispersity index of the nanoparticles in the biological solutions. Moreover, no change in morphology was observed after 48 h as observed by TEM microscopy. Hence, the developed model could prevent the failure of the developed nanosystem during clinical and preclinical application by serving as an initial checkpoint to study their interaction with the complex milieu.
Keywordsex vivo colloidal stability PLGA nanoparticle nanosystem
The authors would like to acknowledge B.V. Patel PERD Centre for providing facility required for the research undertaken, DST for providing financial assistance (IF120807), and NIRMA University.
Compliance of Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotech Biol Med. 2012;8(2):147–66.Google Scholar
- 9.SCENIHR (Scientific Committee on Emerging and Newly-Identified Health Risks), The appropriateness of the risk assessment methodology in accordance with the Technical Guidance Documents for new and existing substances for assessing the risks of nanomaterials; 2007.Google Scholar
- 12.Dar AM, Naseem S, Gatoo MA, Arfat MY, Qasim K. In vivo toxicity of nanoparticles: modalities and treatment. Euro Chem Bullet. 2014;3(10–12):992–00.Google Scholar
- 14.Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L. Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res. 2013;14(6):1–10.Google Scholar
- 17.Hughes AB. Amino acids, peptides and proteins in organic chemistry, Chapter: analysis and function of amino acids and peptides (Amino acids, peptides and proteins in organic chemistry (VCH)). Wiley. 2013;5:298–99.Google Scholar